MediWound Announces NexoBrid Receives Marketing Approval for Burn Treatment in Australia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2025
0mins
Should l Buy MDWD?
Source: NASDAQ.COM
Marketing Authorization Granted: MediWound Ltd. received marketing authorization from Australia's Therapeutic Goods Administration for NexoBrid, an enzymatic therapy for removing eschar in patients with deep partial- and full-thickness thermal burns.
Global Recognition and Launch Plans: NexoBrid is now authorized in 45 countries and is expected to be commercially launched in Australia by Balance Medical in the fourth quarter of 2025, supported by MediWound's manufacturing expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDWD
Wall Street analysts forecast MDWD stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.720
Low
25.00
Averages
30.00
High
36.00
Current: 17.720
Low
25.00
Averages
30.00
High
36.00
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Expert Consensus Supports MediWound's Chronic Wound Treatment Strategy
- Consensus Redefines Debridement: The U.S. multidisciplinary expert panel's consensus redefines debridement as a biologically active intervention that drives healing by reducing biofilm and bacterial burden, providing theoretical support for MediWound's EscharEx® and potentially enhancing its application in the chronic wound care market.
- Importance of Early Treatment: The consensus advocates for prioritizing effective, less invasive treatment methods when appropriate, which not only improves patient treatment experiences but may also reduce healthcare costs, thereby strengthening EscharEx®'s competitive position as a first-line debridement therapy.
- Clinical Research Support: EscharEx® has demonstrated good safety and efficacy in multiple Phase II clinical studies, enabling rapid removal of non-viable tissue and promoting granulation, laying the groundwork for its application in the upcoming Phase III VALUE trial targeting venous leg ulcers, indicating significant market potential.
- Global Market Opportunity: MediWound's innovative EscharEx® therapy for chronic wounds, which combines multiple therapeutic actions, is expected to meet the growing global demand for advanced debridement solutions, further solidifying the company's leadership position in the biotherapeutics field.
See More
MediWound Reports $197 Million BARDA Contract Award to Vericel for NexoBrid
- Significant Contract Value: Vericel has been awarded a ten-year contract by BARDA valued at up to $197 million, with a base contract of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months, indicating strong demand and market potential for the product.
- Strategic Inventory Management: The contract includes the establishment and maintenance of a Vendor Managed Inventory (VMI) system, which will optimize the supply chain management of NexoBrid, ensuring rapid response in emergencies and enhancing the company's competitiveness in the medical emergency sector.
- Manufacturing Capacity Enhancement: The contract also involves plans for the design and validation of a U.S.-based manufacturing facility, which will not only reduce production costs but also enhance Vericel's production capabilities in the U.S. market, further driving NexoBrid's market penetration.
- New Formulation Development: Vericel will develop a next-generation formulation of NexoBrid and explore additional indications for blast trauma treatment, which is expected to broaden the product's applicability and strengthen the company's strategic position in the biopharmaceutical market.
See More
MediWound Ltd. Q4 2025 Earnings Call Insights
- Revenue Decline: Q4 2025 revenue was $1.9 million, down significantly from $5.8 million in Q4 2024, primarily due to reduced development services revenue linked to the U.S. government shutdown, highlighting financial pressures during critical periods.
- Increased R&D Spending: R&D expenses rose from $3 million to $4.5 million, indicating ongoing investment in the EscharEx Phase III clinical trial, which, while increasing short-term financial burdens, lays the groundwork for future product launches.
- Manufacturing Capacity Expansion: The operational launch of the expanded NexoBrid facility increases production capacity sixfold, with regulatory approvals for commercial output expected in 2026, providing robust support for long-term growth in the trauma care market.
- Future Outlook: Management reaffirmed revenue guidance of $24 million to $26 million for 2026, and despite risks associated with reliance on government contracts, the company remains focused on clinical milestones and commercial objectives, demonstrating confidence in future growth.
See More
MediWound Files Annual Report for FY2025
- Annual Report Filing: MediWound Ltd. filed its Form 20-F annual report for the fiscal year ending December 31, 2025, with the SEC on March 5, 2026, reflecting the company's commitment to compliance and transparency to bolster investor confidence.
- Financial Information Access: The annual report is accessible via the SEC's website and the company's investor relations site, demonstrating MediWound's emphasis on information disclosure to enhance shareholders' understanding of its financial health.
- Shareholder Services: The company offers free hard copies of the annual report upon request, showcasing its dedication to shareholder interests and service commitments, which can strengthen shareholder relations.
- Product Pipeline Update: MediWound's FDA-approved product NexoBrid® and investigational therapy EscharEx® highlight the company's innovative capabilities in tissue repair, potentially driving future market growth.
See More
MediWound Q4 Earnings Beat Expectations Despite Revenue Decline
- Earnings Highlight: MediWound reported a Q4 GAAP EPS of -$0.56, beating expectations by $0.07, indicating some improvement in financial management despite overall poor performance.
- Revenue Decline: The company's Q4 revenue of $1.87 million represents a 68% year-over-year decline, missing expectations, which reflects weak market demand and sales challenges that could impact future investor confidence.
- Future Guidance: MediWound reaffirms its revenue guidance of $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028, demonstrating confidence in future growth, particularly relying on support from BARDA and the U.S. Department of War.
- Product Potential: The 2028 outlook includes a potential initial contribution from EscharEx, subject to regulatory approval, which could provide new growth momentum for the company and enhance market expectations regarding its long-term value.
See More
MediWound to Announce Q4 Earnings on March 5
- Earnings Announcement Date: MediWound (MDWD) is set to announce its Q4 2023 earnings on March 5 before market open, with a consensus EPS estimate of -$0.61, reflecting a significant 69.4% year-over-year decline, indicating substantial profitability challenges for the company.
- Revenue Expectations Decline: The anticipated revenue for Q4 is $2.09 million, down 64.2% year-over-year, highlighting the company's struggles with market competition and product demand, which could impact future liquidity and investor confidence.
- Historical Performance Review: Over the past two years, MediWound has only beaten EPS estimates 38% of the time and revenue estimates 63% of the time, indicating considerable performance volatility that may lead to cautious investor sentiment regarding future results.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have experienced no upward revisions and four downward revisions, suggesting a generally pessimistic outlook from analysts on the company's future performance, which could affect stock price movements.
See More
U.S. Expert Consensus Supports MediWound's Chronic Wound Treatment Strategy
- Consensus Redefines Debridement: The U.S. multidisciplinary expert panel's consensus redefines debridement as a biologically active intervention that drives healing by reducing biofilm and bacterial burden, providing theoretical support for MediWound's EscharEx® and potentially enhancing its application in the chronic wound care market.
- Importance of Early Treatment: The consensus advocates for prioritizing effective, less invasive treatment methods when appropriate, which not only improves patient treatment experiences but may also reduce healthcare costs, thereby strengthening EscharEx®'s competitive position as a first-line debridement therapy.
- Clinical Research Support: EscharEx® has demonstrated good safety and efficacy in multiple Phase II clinical studies, enabling rapid removal of non-viable tissue and promoting granulation, laying the groundwork for its application in the upcoming Phase III VALUE trial targeting venous leg ulcers, indicating significant market potential.
- Global Market Opportunity: MediWound's innovative EscharEx® therapy for chronic wounds, which combines multiple therapeutic actions, is expected to meet the growing global demand for advanced debridement solutions, further solidifying the company's leadership position in the biotherapeutics field.
See More
MediWound Reports $197 Million BARDA Contract Award to Vericel for NexoBrid
- Significant Contract Value: Vericel has been awarded a ten-year contract by BARDA valued at up to $197 million, with a base contract of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months, indicating strong demand and market potential for the product.
- Strategic Inventory Management: The contract includes the establishment and maintenance of a Vendor Managed Inventory (VMI) system, which will optimize the supply chain management of NexoBrid, ensuring rapid response in emergencies and enhancing the company's competitiveness in the medical emergency sector.
- Manufacturing Capacity Enhancement: The contract also involves plans for the design and validation of a U.S.-based manufacturing facility, which will not only reduce production costs but also enhance Vericel's production capabilities in the U.S. market, further driving NexoBrid's market penetration.
- New Formulation Development: Vericel will develop a next-generation formulation of NexoBrid and explore additional indications for blast trauma treatment, which is expected to broaden the product's applicability and strengthen the company's strategic position in the biopharmaceutical market.
See More
MediWound Ltd. Q4 2025 Earnings Call Insights
- Revenue Decline: Q4 2025 revenue was $1.9 million, down significantly from $5.8 million in Q4 2024, primarily due to reduced development services revenue linked to the U.S. government shutdown, highlighting financial pressures during critical periods.
- Increased R&D Spending: R&D expenses rose from $3 million to $4.5 million, indicating ongoing investment in the EscharEx Phase III clinical trial, which, while increasing short-term financial burdens, lays the groundwork for future product launches.
- Manufacturing Capacity Expansion: The operational launch of the expanded NexoBrid facility increases production capacity sixfold, with regulatory approvals for commercial output expected in 2026, providing robust support for long-term growth in the trauma care market.
- Future Outlook: Management reaffirmed revenue guidance of $24 million to $26 million for 2026, and despite risks associated with reliance on government contracts, the company remains focused on clinical milestones and commercial objectives, demonstrating confidence in future growth.
See More
MediWound Files Annual Report for FY2025
- Annual Report Filing: MediWound Ltd. filed its Form 20-F annual report for the fiscal year ending December 31, 2025, with the SEC on March 5, 2026, reflecting the company's commitment to compliance and transparency to bolster investor confidence.
- Financial Information Access: The annual report is accessible via the SEC's website and the company's investor relations site, demonstrating MediWound's emphasis on information disclosure to enhance shareholders' understanding of its financial health.
- Shareholder Services: The company offers free hard copies of the annual report upon request, showcasing its dedication to shareholder interests and service commitments, which can strengthen shareholder relations.
- Product Pipeline Update: MediWound's FDA-approved product NexoBrid® and investigational therapy EscharEx® highlight the company's innovative capabilities in tissue repair, potentially driving future market growth.
See More
MediWound Q4 Earnings Beat Expectations Despite Revenue Decline
- Earnings Highlight: MediWound reported a Q4 GAAP EPS of -$0.56, beating expectations by $0.07, indicating some improvement in financial management despite overall poor performance.
- Revenue Decline: The company's Q4 revenue of $1.87 million represents a 68% year-over-year decline, missing expectations, which reflects weak market demand and sales challenges that could impact future investor confidence.
- Future Guidance: MediWound reaffirms its revenue guidance of $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028, demonstrating confidence in future growth, particularly relying on support from BARDA and the U.S. Department of War.
- Product Potential: The 2028 outlook includes a potential initial contribution from EscharEx, subject to regulatory approval, which could provide new growth momentum for the company and enhance market expectations regarding its long-term value.
See More
MediWound to Announce Q4 Earnings on March 5
- Earnings Announcement Date: MediWound (MDWD) is set to announce its Q4 2023 earnings on March 5 before market open, with a consensus EPS estimate of -$0.61, reflecting a significant 69.4% year-over-year decline, indicating substantial profitability challenges for the company.
- Revenue Expectations Decline: The anticipated revenue for Q4 is $2.09 million, down 64.2% year-over-year, highlighting the company's struggles with market competition and product demand, which could impact future liquidity and investor confidence.
- Historical Performance Review: Over the past two years, MediWound has only beaten EPS estimates 38% of the time and revenue estimates 63% of the time, indicating considerable performance volatility that may lead to cautious investor sentiment regarding future results.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have experienced no upward revisions and four downward revisions, suggesting a generally pessimistic outlook from analysts on the company's future performance, which could affect stock price movements.
See More
